Disclosure Of Rights Attached To Equity Shares

RNS Number : 8547K

Mediclinic International plc

24 April 2020

 

Mediclinic International plc

(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC

JSE Share Code: MEI
NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic" , the " Company ", or the "Group" )

24 April 2020

Listing Rule 9.2.6E Confirmation
(Disclosure of rights attached to equity shares)

In accordance with paragraph 9.2.6E (disclosure of rights attached to equity shares) of the Listing Rules of the Financial Conduct Authority (the "FCA"), which comes into effect on 27 April 2020, the Company has today forwarded to the FCA for publication on the National Storage Mechanism ("NSM") a document setting out the changes which have occurred in relation to the rights attached to the Company's listed equity shares since the publication of its prospectus on 19 November 2015 (the "Prospectus"), namely the redemption of the 50,000 redeemable non-voting preference shares of £1.00 and the repurchase and cancellation of the 10 subscriber shares of £0.10 each, as anticipated in the Prospectus, which were completed in 2016.

There have been no changes to the rights attached to the ordinary shares of the Company since the publication of the Prospectus.

The NSM can be accessed at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

About Mediclinic International plc

Mediclinic is an international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates.

The Group's core purpose is to enhance the quality of life.

Its vision is to be the partner of choice that people trust for all their healthcare needs.

Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.

Mediclinic comprises 77 hospitals, five sub-acute hospitals, 15 day case clinics and 22 outpatient clinics. Hirslanden operates 17 hospitals, three day case clinics and three outpatient clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operations include 53 hospitals (three of which in Namibia), five sub-acute hospitals and 10 day case clinics (four of which are operated by Intercare) across South Africa, and more than 8 500 inpatient beds; and Mediclinic Middle East operates seven hospitals, two day case clinics and 19 outpatient clinics with more than 900 inpatient beds in the United Arab Emirates.

The Company's primary listing is on the London Stock Exchange ("LSE") in the United Kingdom, with secondary listings on the JSE Ltd in South Africa and the Namibian Stock Exchange in Namibia.

Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Ben Atwell/Ciara Martin - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address : 6^th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website:   www.mediclinic.com  

Corporate broker : Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)

NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd

 

END

 

 

MSCBSGDSCXDDGGS